CEPI to Support Development of Self Amplifying mRNA Vaccine Technology for Use Against Disease X
OSLO, Norway CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. Funding will support optimisation of the technology platform to enhance immunogenicity. The Coalition for Epidemic Preparedness Innovations (CEPI) and Pune-based Gennova Biopharmaceuticals Ltd, today announced […]








